Nasdaq stocks posting largest volume increases
AP - Thu Apr 23, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CALI: 2.28 (-0.05), ENZN: 1.72 (+0.18), PCMI: 9.72 (+0.32), URRE: 1.41 (-0.05), HMTV: 12.86 (+0.16), SCYX: 9.47 (-0.52), ARTW: 5.23 (+0.07), VIDE: 2.25 (+0.02), PKT: 11.43 (-0.02), PLMT: 18.58 (+0.54), MNRK: 12.28 (+0.05)
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 23, 12:25PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
AMSC: 6.88 (-3.12), VCYT: 9.63 (+0.40), ASPS: 23.24 (+0.76), OFLX: 29.59 (+0.39), SCYX: 9.47 (-0.52), ANGI: 6.16 (-0.24), VASC: 35.31 (+0.45), PKT: 11.43 (-0.02), GLUU: 5.45 (+0.09), ASML: 107.16 (-1.53), DWCH: 7.76 (-0.34)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 11:45AM CDT
CERS: 4.79 (+0.20), HBP: 3.84 (-0.10), CIDM: 0.95 (-0.02), HNI: 51.98 (+0.71), MDSO: 57.59 (+0.05), HZO: 22.88 (-1.52), NKA: 2.06 (+0.06), NVGN: 6.54 (-0.01), EGT: 2.18 (-0.02), VLTC: 11.54 (+0.50), ADPT: 63.78 (+2.13), CALI: 2.28 (-0.05), XXII: 1.35 (-0.05), LOOK: 1.97 (+0.37), ARRS: 35.76 (-1.54), SIFY: 1.46 (-0.14), SCYX: 9.47 (-0.52), CLFD: 14.25 (+0.04), VGGL: 2.55 (-0.10), MOBL: 6.97 (-0.14)
SCYNEXIS Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Apr 22, 9:30PM CDT
Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of 4,675,324 shares of its common stock at a public offering price of $7.70 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by SCYNEXIS. In addition, SCYNEXIS has granted the underwriters a 30-day option to purchase up to an additional 701,298 shares of common stock at the public offering price less the underwriting discounts and commissions to cover over-allotments, if any.
SCYX: 9.47 (-0.52)
Scynexis initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 9:29AM CDT
SCYX: 9.47 (-0.52)
SCYNEXIS Announces Launch of Public Offering of Common Stock
GlobeNewswire - Mon Apr 20, 6:40AM CDT
SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the commencement of an underwritten public offering of shares of its common stock and expects to raise gross proceeds of up to $30 million. The company expects to grant the underwriter a 30-day option to purchase up to an additional $4.5 million of shares of its common stock in connection with the offering. All of the shares of common stock in the offering will be sold by SCYNEXIS.
SCYX: 9.47 (-0.52)
Scynexis net loss improves in FY14
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:45AM CDT
SCYX: 9.47 (-0.52)
SCYNEXIS misses by $1.13, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 7:37AM CDT
SCYX: 9.47 (-0.52)
SCYNEXIS, Inc. Reports Full Year 2014 Financial Results
GlobeNewswire - Mon Mar 30, 7:30AM CDT
Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the year ended December 31, 2014.
SCYX: 9.47 (-0.52)
SCYNEXIS, Inc. to Present at Jefferies 2015 Antibiotic Summit
GlobeNewswire - Thu Mar 12, 7:30AM CDT
Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that members of the SCYNEXIS executive management team will present at the Jefferies 2015 Antibiotic Summit hosted by Eun Yang at the Jefferies Offices in New York City on Wednesday, March 18, 2015, at 2:10 p.m. ET.
SCYX: 9.47 (-0.52)
SCYNEXIS, Inc. to Present at RBC Capital Markets 2015 Healthcare Conference
GlobeNewswire - Thu Feb 19, 7:30AM CST
Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that Yves J. Ribeill, Ph.D., SCYNEXIS' CEO and President, will present at the RBC Capital Markets 2015 Healthcare Conference at the New York Palace Hotel in New York City on Tuesday, February 24, 2015, at 3:05 p.m. ET.
SCYX: 9.47 (-0.52)
Management transitions at Scynexis
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 6:42AM CST
SCYX: 9.47 (-0.52)
SCYNEXIS Names Marco Taglietti, M.D., Chief Executive Officer
GlobeNewswire - Fri Feb 06, 6:15AM CST
Yves Ribeill, Ph.D., to Remain President, Serve on Board of Directors
SCYX: 9.47 (-0.52)